Research programme: porphyrin-based cancer therapeutics - OncoSelect Therapeutics
Latest Information Update: 14 Jul 2016
At a glance
- Originator OncoSelect Therapeutics
- Developer OncoSelect Therapeutics; University of Texas Health Science Center at San Antonio
- Class Porphyrins
- Mechanism of Action Image enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 23 Jun 2016 Early research in Cancer in USA (Parenteral)